Detection of benzimidazole carbamates and amino metabolites in liver by surface plasmon resonance-biosensor by Keegan, Jemma et al.
TITLE: Detection of benzimidazole carbamates and amino metabolites in liver by surface plasmon
resonance-biosensor
AUTHORS: Jemma Keegan, Richard O’Kennedy, Steven Crooks, Christopher Elliott, David Brandon,
Martin Danaher
This or(s) and Teagasc T-Stór in accordance with publisher policies.
ase cite the published version.
is available in the T-Stór record for this article.
Th
NOT
This rk that was accepted for publication in Analytica Chimica Acta.
Chan ing process, such as peer review, editing, corrections, structural
form l mechanisms may not be reflected in this document. Changes may
have it was submitted for publication. A definitive version was
subse a Chimica Acta, 2011, 700 (1-2), 41-48. DOI:
10.10article is provided by the auth
Ple
The correct citation
ICE:
is the author’s version of a wo
ges resulting from the publish
atting, and other quality contro
been made to this work since
quently published in Analytic
16/j.aca.2010.12.0411
is item is made available to you under the Creative Commons Attribution-Non commercial-No
Derivatives 3.0 License.
21 Detection of benzimidazole carbamates and amino metabolites in liver by surface
2 plasmon resonance-biosensor
3
4 Jemma Keegana,b, Richard O’Kennedyb, Steven Crooksc, Christopher Elliottd, David
5 Brandone and Martin Danahera*
6
7 aTeagasc Food Research Centre, Ashtown, Dublin 15, Ireland
8 bSchool of Biotechnology and National Centre for Sensor Research, Dublin City
9 University, Dublin 9, Ireland
10 cVeterinary Sciences Division, Agri-Food & Biosciences Institute, Belfast, Northern
11 Ireland
12 dI nstitute of Agri-Food and Land Use, School of Biological Sciences, Queen’s University
13 Belfast, Belfast, Northern Ireland
14 eWestern RegionalResearch Center, US Department of Agriculture, Agricultural Research
15 Service, Albany, CA, USA
16
17 *Corresponding author
18 Email: martin.danaher@teagasc.ie
19 Phone: 353-1-8059552
20 Fax: 353-1-8059550
21
22 Abstract
23 Two surface plasmon resonance (SPR) biosensor screening assays were developed and
24 validated to detect 11 benzimidazole carbamate (BZT) and four amino-benzimidazole
25 veterinary drug residues in liver tissue. The assays used polyclonal antibodies, raised in
26 sheep, to detect BZTs and amino-benzimidazoles. A modified Quick, Easy, Cheap,
27 Effective, Rugged and Safe (QuEChERS) extraction method was developed to isolate
28 benzimidazole carbamate residues. Liver samples were extracted using an acetonitrile
29 extraction method. BZTs were purified by dispersive solid phase extraction (d-SPE) using
30 C18 sorbent. Residues of amino-benzimidazoles were effectively cleaned-up using a simple
31 cyclohexane defatting step. The assays were validated in accordance with the performance
32 criteria described in 2002/657/EC. The BZT assay limit of detection was calculated to be
33 32 µg kg-1, the detection capability (CCβ) was determined to be 50 µg kg-1 and the mean
334 recovery of analytes was in the range 77-132%. The amino-benzimidazole assay limit of
35 detection was determined to be 41 µg kg-1, the CCβ was determined to be 75 µg kg-1 and
36 analyte recovery was in the range 103-116%. Biosensor assay performance was tested by
37 analysing liver tissue from animals treated with benzimidazole drugs and comparing the
38 results with an ultra high performance liquid chromatography tandem mass spectrometry
39 (UHPLC-MS/MS) confirmatory method. All non-compliant samples were identified using
40 the biosensor assays.
41
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44
45 1. Introduction
46 Benzimidazoles are anthelmintic agents with broad spectrum activity against nematodes,
47 cestodes and trematodes. They are widely used for treatment of food producing animals in
48 the European Union (EU). Many benzimidazole drugs have been proven to be safe when
49 product label claims are followed. However, some drugs have shown teratogenic
50 properties and congenital malformations have been reported in gestating ewes after the
51 administration of albendazole and oxfendazole ABZ and OFZ [1]. Hence concern has been
52 raised that high levels of residues may affect developing embryos in pregnant women.
53 Maximum residue limits (MRLs) have been established in the EU for benzimidazole
54 residues in edible tissues to protect public health under Commission Regulation
55 2010/37/EC. In addition, annual surveillance programmes are carried out in member states
456 under Council Directive 96/23/EC. Results from this surveillance highlight the need for
57 continued monitoring of benzimidazole residues due to sporadic incidences of non-
58 compliant benzimidazole residues in milk and meat [2].
59
60 Several assays have been reported for benzimidazoles in liver because residues are known
61 to accumulate in this organ making it an ideal target tissue for residue surveillance
62 purposes. Marti et al. developed a HPLC-UV method to detect eight benzimidazole
63 residues in liver tissue using an acetonitrile extraction followed by purification with
64 multiple liquid-liquid partitioning (LLP) and solid phase extraction (SPE) steps [3].
65 Wilson et al. subsequently developed a simpler method based on ethyl acetate extraction
66 coupled with purification by LLP (acidified ethanol versus hexane) and a further C2 SPE
67 clean-up step prior to HPLC-UV analysis [4]. This method has been used in many
68 laboratories, but analyte coverage has been limited both by inadequate HPLC resolution
69 and the poor availability of analytical standards [5]. The method has been extended to 12
70 benzimidazole residues but the throughput of the assay has been limited in our laboratory
71 to 38 samples and associated controls per week for a single analyst [6]. Other groups have
72 increased the analytical scope and throughput of methods using liquid chromatography
73 coupled to mass spectrometry [7]. However, this technology requires a significant amount
74 of consumables, extensive maintenance for effective continued operation and experienced
75 operators to process results. Ideally a method should include a wide range of
76 benzimidazole marker residues as listed in Table 1. The inclusion of metabolites is
77 important because they can be more toxic and persist longer than the parent drug [8-10].
78
579 Enzyme linked immunosorbent assays (ELISAs) have been developed by some groups for
80 detecting benzimidazole residues as easier and low cost alternatives to chemical assays
81 [11]. Immunoassays can also offer similar selectivity and sensitivity to that of LC-MS/MS.
82 However, they are slow because of the multiple washing and incubation steps required and
83 have proved difficult to automate in food analysis [12]. In addition, ELISAs with good
84 repeatability can be difficult to develop and results are frequently non-quantitative and
85 susceptible to matrix effects. Alternatively, several surface plasmon resonance (SPR)
86 optical biosensor assays have been developed for detecting low levels of contaminant
87 residues in food [13-15]. SPR is advantageous because labelling of antibodies or enzymes
88 is not required. Furthermore, assay performance is frequently enhanced through
89 automation and real time analysis. Crooks et al. highlighted the advantage of SPR
90 biosensor over ELISA for analysing sulphonamide residues in 2081 pig bile samples over
91 an eight month period [16]. False positive rates of 0.14 to 0.34% and 1.44 to 1.54% were
92 observed for SPR-biosensor and ELISA, respectively. No false negative results were
93 observed using SPR biosensor, while ELISA false negative rates were 0.14 to 0.24%.
94 The cost of SPR biosensors is higher than ELISA but savings can be seen through
95 automation, which reduces labour costs and improves reliability of results. A further
96 advantage of the technique is the ease of assay transfer between laboratories through
97 reduction of operator effects through the elimination of plate washing and incubation steps.
98 In addition, clear advantages of SPR biosensor assay can be seen over traditional HPLC
99 based detection systems, which are frequently dedicated to specific assays, require
100 laborious sample preparation and take longer to set-up prior to analysis. A typical SPR
101 biosensor system can handle as many as five different assays in a single week because of
6102 the speed of changeover. In addition, recent advances in instrumentation have highlighted
103 the ability to multiplex assays and improve sample throughput [17].
104
105 Recently a biosensor screening assay for benzimidazole carbamate residues in milk was
106 developed using a modified QuEChERS extraction [18]. Due to limitations in the cross-
107 reactivity of the antibody this assay could not detect a number of key metabolites
108 possessing amino functional groups. The assay was found to be suitable for screening
109 residues in incurred milk samples to below the MRL but extension to amino metabolites is
110 desirable to provide more quantitative results. The aim of this study was to develop and
111 validate multi-residue SPR biosensor assays to screen liver tissue samples for 11
112 benzimidazoles and four amino-benzimidazole residues. The suitability of the assays to
113 detect residues in liver tissue was verified through application of each assay to samples that
114 were previously shown to contain benzimidazole residues by UHPLC-MS/MS. The
115 method was validated according to 2002/657/EC [19].
116
117
118 2. Materials and methods
119
120 2.1 Chemicals, reagents and apparatus
121 CM5 sensor chips (research grade), 96 well polystyrene microplates, NHS (100 mM N-
122 hydroxysuccinimide in water), EDC (400 mM 1 -ethyl-3 -(3 -dimethylaminopropyl)-
7123 carbodiimide hydrochloride in water), 1 M ethanolamine and HBS-EP buffer (10 mM
124 H EPES pH 7.4 with 0.05 M NaCl, 3.4 mM EDTA) and 0.005% (v/v) P20 were all obtained
125 from GE Healthcare (Uppsala, Sweden). Ultra-pure water (18.2 MΩ) was generated in-
126 house using a Millipore water purification system (Cork, Ireland). Sodium hydroxide
127 (NaOH), pesticide grade acetonitrile (MeCN), pesticide grade dimethylsulphoxide
128 (DMSO), pesticide grade ethyl acetate, cyclohexane and methanol were supplied by
129 BDH/VWR international Ltd. (Poole, England, UK). Ethylenediamine (99%, v/v),
130 dimethylformamide (DMF), albendazole (ABZ), mebendazole (MBZ) and fenbendazole
131 (FBZ) were supplied by Sigma Aldrich (Steinheim, Germany). Oxibendazole (OXI),
132 fenbendazole-sulphoxide (FBZ-SO) and flubendazole (FLU) were purchased from QMX
133 laboratories (Thaxted, UK). Amino-flubendazole (FLU-NH2), amino-mebendazole (MBZ-
134 NH2), hydroxy-mebendazole (MBZ-OH), and hydroxy-flubendazole (FLU-OH) were
135 received as a gift from Janssen pharmaceuticals (Belgium). Albendazole-2-amino-
136 sulphone (ABZ-NH2-SO2), albendazole sulphone (ABZ-SO), albendazole sulphoxide
137 (ABZ-SO), fenbendazole sulphone (FBZ-SO2) and amino-oxibendazole (OXI-NH2) were
138 purchased from Witega laboratories (Berlin, Germany). Polypropylene centrifuge tubes
139 with screw caps (50 mL) containing 4 g magnesium sulphate (MgSO4) and 1 g NaCl were
140 supplied by United Chemical Technologies (Bristol, PA, USA). Polypropylene tubes (50
141 mL) containing 1.5 g magnesium sulphate (MgSO4) and 0.5 g C18 were purchased from
142 Biotage (Uppsala, Sweden). The amino-albendazole hapten (Lot no. LK515) stored at -
143 20ºC was received from Randox Life Sciences (Antrim, Northern Ireland). Whatman®
144 syringe filter units (polytetrafluoroethylene (PTFE), 0.2 µm) were purchased from Fisher
145 Scientific (Dublin, Ireland). Primary standard stock solutions (1 mg mL-1) for each
146 benzimidazole were prepared in DMSO. Working standard solutions were then prepared at
8147 40 µg mL-1 by diluting the primary stock in methanol. A FASTH 21 homogenisation unit
148 and sample homogenisation tubes were supplied by Syntec Scientific (Dublin, Ireland), a
149 Mistral 3000i centrifuge (MSE, London, UK), an Elma Transsonic T780/H ultrasonic bath
150 (Bedford, UK) and a Turbovap LV evaporator (Caliper Life Sciences, Runcorn, UK) were
151 used during sample preparation.
152
153 2.2 Liver samples
154
155 2.2.1 Negative control samples
156 Ovine liver samples found to be free of benzimidazole residues by UHPLC-MS/MS, with a
157 limit of detection (LOD) of <1 µg kg-1, were used as negative controls.
158 2.2.2 Incurred liver samples
159 The suitability of the assay to detect residues was evaluated through application to fortified
160 and naturally positive samples. Liver tissue samples purchased from a supermarket
161 (samples 1-7) were tested to establish the performance of the assay when low levels of
162 benzimidazole residues are present. To prepare incurred samples, three 16-month old
163 steers were dosed orally with mebendazole (sample 8), fenbendazole (sample 9) and
164 albendazole (sample 10) at 15, 7.5 and 5 mg kg-1 body weight, respectively. The animals
165 were humanely euthanized after 24 h and the livers were collected and stored at -20°C until
166 analysis. The UHPLC-MS/MS sample preparation, detection conditions and calibration
167 method used in this work were outlined in recent work reported by Kinsella et al. [20].
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169 2.3 SPR-Biosensor Assays
170 2.3.1 Sample preparation
171 A modified QuEChERS extraction method was used to isolate benzimidazole carbamate
172 residues from liver tissue. Finely chopped liver (2 g) was homogenised in a slurry
173 containing MeCN:MgSO4:NaCl (12:4:1, v/w/w), homogenised (30 sec in a multi-
174 homogenisation unit) and centrifuged (3,000 ×g, 10 min, -5°C). The supernatant was
175 transferred to a tube containing C18 sorbent (500 mg) and MgSO4 (1.5 g). The tubes were
176 subsequently shaken (1 min) and centrifuged (3500 ×g, 10 min, -5°C). The MeCN layer (6
177 mL) was transferred to polypropylene tubes and DMSO (500 µL) was added. The MeCN
178 was evaporated under nitrogen at 50°C using a Turbovap LV (Caliper Life Sciences,
179 Runcorn, UK). The DMSO extracts were vortexed (2 min) and sonicated (10 min).
180 Amino-benzimidazole residues were extracted using the same procedure as for the
181 carbamate metabolites but did not undergo C18 clean-up. Instead, DMSO extracts were
182 defatted with cyclohexane (2 × 2 mL aliquots), and the cyclohexane layer was removed by
183 aspiration. DMSO sample extracts were vortexed (2 min) and sonicated (10 min).
184
185 2.3.2 SPR-biosensor chip preparation
186 The preparation of the biosensor chip for benzimidazole carbamate was described in
187 previous work by this research group [18].
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188 A new CM5 biosensor chip was prepared for amino-benzimidazoles. Firstly the chip was
189 left to equilibrate to room temperature (20 min). HBS-EP buffer (50 µL) was added to
190 each chip surface and incubated (10 min). The buffer was removed and 50 mM NHS:200
191 mM EDC (1:1, v/v, 40 µL) was added to the chip and incubated (20 min, room
192 temperature) to activate the surface. This solution was removed from the surface. An
193 amine surface was prepared by adding 1 M ethylenediamine (50 µL) to the surface (1 h,
194 room temperature). The solution was removed using lint-free tissue paper. A carboxy-
195 amino-albendazole derivative (2.5 mg) was dissolved in DMF (1 mL), vortexed (2 min)
196 and sonicated (15 min). EDC (1.825 mg) and NHS (1.25 mg) were added to this solution
197 and incubated at room temperature (3 h) to activate the carboxyl groups of the amino-
198 benzimidazole derivative to form o-acylisourea intermediates with a COOH function. The
199 remaining unreacted groups on the chip surface were deactivated by addition of 1 M
200 ethanolamine-HCl (50 µL) and allowed to react (20 min). Following immobilization, the
201 chip was washed five times with HBS-EP buffer and dried under a nitrogen stream. The
202 amino-albendazole immobilized chip was stored in a Sarstedt® tube containing silica
203 crystals (4°C) when not in use.
204
205 2.3.3 SPR-biosensor analytical cycle
206 The optical biosensor used was a Biacore Q (GE Healthcare, Uppsala Sweden) with
207 Biacore®Q control software version 3.0. BIAevaluation software 3.0.1 was used for data
208 handling. Studies were conducted at 25°C and all samples and calibrants were analysed in
209 duplicate.
210 Polyclonal antibody, raised in sheep against 5(6)-[(carboxypentyl)-thio]-2-
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211 benzimidazolecarbamate derivative (CMB) coupled to human serum albumin (HSA), was
212 received from the Veterinary Sciences Division, Agri-Food and Biosciences Institute,
213 Belfast, Northern Ireland and was used for the benzimidazole carbamate assay. An
214 antibody dilution of 1/1000 (v/v), was found to give satisfactory results under assay
215 conditions. DMSO extracts were transferred to 96 well microplates and mixed (1:9, v/v)
216 with antibody and passed over the immobilised surface at 10 µL min-1 (2 min).
217 Regeneration of the chip was carried out by sequential injection of 25 mM HCl (15 µL)
218 followed by 180 mM NaOH (20 µL) across the chip at 25 µL min-1.
219 Polyclonal sheep antibody raised against amino-albendazole coupled to bovine
220 thyroglobulin (BTG) was from Randox Laboratories (Crumlin, Northern Ireland) and was
221 used for amino-benzimidazole detection. The Ig fraction (2.4 mg mL-1 in phosphate-
222 buffered saline containing 0.09% sodium azide) was diluted 1/400 (v/v), to give
223 satisfactory results under assay conditions. DMSO sample extracts were diluted in HBS-
224 EP buffer (1:4, v/v), added to a 96 well microplate and mixed with (1:4, v/v) antibody and
225 passed over the chip surface at 10 µL min-1 (3 min). Regeneration of the chip was carried
226 out by sequential injection of 25 mM HCl (15 µL) and 170 mM NaOH (20 µL) at 25 µL
227 min-1. The binding of the antibody to the chip surface was measured as the change in SPR
228 signal between two report points, 10 sec before and 30 sec after each injection. A
229 competitive immunoassay format was used to detect inhibition of antibody binding to the
230 chip surface. The SPR signal was expressed in arbitrary resonance units (RU).
231
232 2.4 Calibration
233 Benzimidazole residue-free liver samples were fortified with albendazole-sulphone (ABZ-
12
234 SO2) at levels of 0, 50, 100, 250, 500 and 1000 µg kg-1 to prepare an extract calibration
235 curve for the benzimidazole carbamate assay. Similarly samples were fortified with
236 albendazole-amino-sulphone (ABZ-NH2-SO2) at levels of 0, 25, 50, 75, 125, 250 and 500
237 µg kg-1 to prepare an extract calibration curve for the amino-benzimidazole assay.
238 BIAevaluation software was used to construct inhibition assay standard curves based on a
239 4-parameter fit.
240
241 2.5 Method validation
242 A qualitative approach was used to determine the performance factor CCβ (detection
243 capability) as described in 2002/657/EC criteria [19]. Firstly, the limit of detection (LOD)
244 of the assay was determined by measuring the mean response for 20 different negative
245 ovine liver tissue samples and subtracting three standard deviations. CCβ is the
246 concentration at which a substance can be identified as positive (>LOD) with a statistical
247 certainty of (1-β), where β = 5%. In order to determine CCβ for each assay, samples (n =
248 20 for each analyte) were spiked at a concentration above the LOD. If 19 of the 20
249 fortified samples were identified as positive, CCβ was to be determined to be equal to the
250 fortification level (5% probability of a false negative result). If 20 samples were identified
251 as positive, CCβ was determined to be less than the fortification level and if ≤18 samples
252 were identified as positive, CCβ was determined to be greater than the fortification level.
253 Liver samples were fortified at arbitrary concentrations above the LOD of each assay and
254 through trial and error CCβ levels were determined. Assay repeatability was evaluated by
255 extracting and analysing ovine liver fortified with each analyte on five separate days.
256
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257
258 3. Results and discussion
259
260 3.1 Development of sample preparation procedures
261 Several sample preparation procedures have been developed for the isolation of
262 benzimidazole residues from liver tissue based on liquid-liquid extraction with a water
263 immiscible solvent such as ethyl acetate. An ethyl acetate extraction procedure (extraction
264 procedure I) based on the method reported by Dowling et al. [9] was evaluated for the
265 isolation of benzimidazole carbamates from liver tissue. The automated SPE clean-up step
266 was omitted because it was considered unsuitable for a rapid method. After centrifugation,
267 the ethyl acetate supernatant was reduced to dryness under nitrogen (50°C) and
268 resuspensed in MeOH:water (50:50, v/v). This extract was diluted (1/20, v/v) in HBS-EP
269 buffer prior to biosensor analysis. Extracted matrix calibration curves prepared over the
270 range 0 to 2000 μg kg-1 (ABZ-SO equivalents) showed significant lower sensitivity (IC50 =
271 770 µg kg-1) when compared to buffer curves (IC50 = 88 μg kg-1) (Fig. 1). Losses in
272 recovery were due to adsorption of analytes onto filter paper containing sodium sulphate.
273 Subsequently the sample preparation procedure was modified by reducing the weights of
274 sample and sodium sulphate (extraction procedure II) but this resulted in only slight
275 improvements in sensitivity (IC50 = 625 µg kg-1).
276
277 An alternative MeCN extraction was next evaluated for isolating benzimidazoles from liver
278 tissue [6]. MeCN is an attractive solvent for isolating benzimidazole residues from
14
279 biological samples without pH adjustment, extracts a lower quantity of fat and precipitates
280 protein. Simple liquid-liquid partitioning steps were employed based on cyclohexane and a
281 saturated aqueous NaCl wash to remove non-polar and polar matrix components,
282 respectively. This sample preparation approach resulted in a significant improvement in
283 sensitivity. The calibration curve in liver matrix showed an IC50 of 89 µg kg-1 (extraction
284 procedure III), not significantly different from the IC50 (88 µg kg-1) in buffer. However, the
285 sensitivity required for the recovery for ABZ and FBZ residues was unsatisfactory at
286 <40%.
287 In earlier work by the present research group, a QuEChERs sample preparation procedure
288 had been successfully applied to the analysis of 11 benzimidazole residues in milk samples.
289 However, we evaluated an alternative clean-up procedure for liver tissue analysis because
290 of the lower sensitivity required. A QuEChERs sample preparation procedure was applied
291 to fortified ovine liver extracts, and the calibration curve showed comparable sensitivity
292 (IC50 = 86 µg kg-1) to MeCN and buffer curves. In addition, recoveries of ABZ and FBZ
293 were acceptable, and the assay proceeded to validation. Subsequently, a new antibody
294 became available that showed specificity towards amino-benzimidazole metabolites.
295 Initially, the d-SPE procedure described in section 2.3.1 was used for amino-benzimidazole
296 extraction but showed consistently low recovery of <50% for FLU-NH2, MHZ-NH2 and
297 OXI-NH2 residues. Spiking experiments verified that this loss occurred at the clean-up
298 stage. Alternative clean-up methods were investigated using different brands of C18
299 sorbents, high speed centrifugation (18000 x g), and washing with cyclohexane. Liquid-
300 liquid partitioning with cyclohexane showed the highest recovery levels for all amino-
301 metabolites and was selected for further validation.
302
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303 3.2 Antibody inhibition studies
304 The cross-reactivity of the benzimidazole carbamate (S48) polyclonal antibody was
305 determined in previous work by analysing inhibition curves obtained for each of 11
306 analytes in buffer by the SPR-biosensor assay [18]. The cross-reactivity of the S48
307 antibody towards 11 benzimidazole carbamates was determined by analysing inhibition
308 curves in ovine liver tissue (0-1000 µg kg-1) using the QuEChERS method. IC50 values in
309 matrix ranged from 78 to 95 µg kg-1 for FBZ-SO and FBZ, respectively, and cross-
310 reactivities at 50% inhibition (CR50) were 110 and 91% respectively (Table 2). Matrix
311 calibration curves for 11 benzimidazole carbamates are shown in Fig. 2.
312 The cross-reactivity of the anti-amino-benzimidazole polyclonal antibody (PAS 9869) was
313 determined by analysing inhibition curves with analyte concentrations from 0 - 125 ng mL-
314 1 prepared in HBS-EP buffer and from 0 - 500 µg kg-1 in ovine liver tissue. In buffer the
315 antibody showed significant cross-reactivity with four amino-benzimidazoles (80 to 125%)
316 in the following order of affinity OXI-NH2>MBZ-NH2>ABZ-NH2-SO2>FLU-NH2 and
317 analyte IC50 values were typically less than 7.1 ng mL-1 (Table 2). IC50 values in matrix
318 ranged from 35 to 55 µg kg-1 for the four amino analytes. Matrix calibration curves for
319 four amino-benzimidazoles are shown in Fig. 3.
320
321 3.3 Method Validation
322
323 3.3.1. Benzimidazole carbamate biosensor assay
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324 The dynamic range of the assay was found to be from 7 µg kg-1 (IC10) to 340 µg kg-1 (IC90)
325 and the IC50 was calculated to be 86 µg kg-1. The LOD was determined to be 32 µg kg-1 by
326 measuring the mean response of 20 representative blank ovine liver samples (459 RU) and
327 subtracting three standard deviations (3 x 24 RU). To determine the CCβ a concentration
328 of 50 µg kg-1 was selected; this is equivalent to one quarter of the concentration of the
329 analyte with the lowest MRL. The results for the determination of CCβ for each analyte
330 are shown in Table 3. The CCβ for ten of the analytes was found to be less than 50 µg kg-1.
331 The CCβ for MBZ-OH was found to be equal to 50 µg kg-1 where one sample was not
332 identified as positive; the false negative sample gave a measured result of 32 µg kg-1.
333 However the method satisfies the false negative rate (5%) as required by 2002/657/EC. The
334 repeatability of the assay was evaluated by analysing fortified ovine liver samples (100 µg
335 kg-1) with the 11 analytes on five separate days (Table 3). Results showed acceptable
336 recovery (77-132%) and inter-assay coefficients of variation (11-17%) for the purposes of a
337 screening method. Calibration curves for each day are shown in Fig. 4(A).
338
339 3.3.2 Amino benzimidazole assay
340 The dynamic range of the assay was found to be from 22 (IC10) to 238 µg kg-1 (IC90) and
341 the IC50 was 44 µg kg-1. The LOD of the assay using was determined to be 41 µg kg-1 by
342 measuring the mean response of 20 representative blank ovine liver samples (236 RU) and
343 subtracting three standard deviations (3 x 21 RU).
344 The CCβ of the assay was determined by fortifying 20 representative blank ovine liver
345 samples at 75 µg kg-1 with four different amino-benzimidazoles. The CCβ for three of the
346 four amino analytes was found to be <75 µg kg-1 because all 20 fortified samples showed
17
347 responses above the LOD (Table 3). The CCβ for FLU-NH2 was equal to 75 µg kg-1 as one
348 of the samples gave a measured result of 40 µg kg-1and was deemed negative. The
349 repeatability of the assay was evaluated by analysing ovine liver samples fortified (125 µg
350 kg-1) with four analytes on five separate days. Results showed acceptable recovery (103-
351 116%) and inter-assay coefficients of variation (8-16%) for the purposes of a screening
352 method (Table 3). Calibration curves for each day are shown in Fig. 4(B).
353
354 3.4 Application of SPR assay to incurred liver tissue
355 The suitability of the SPR biosensor assays was evaluated by analysing three liver tissue
356 samples from bovine animals treated with albendazole, fenbendazole and mebendazole
357 products and seven supermarket samples found to contain benzimidazole residues. The
358 samples were independently analysed by two different analysts using the SPR-biosensor
359 and UHPLC-MS/MS methods. Seven of the nine samples were found to contain
360 benzimidazole residues at concentrations above the LOD, which was 32 and 41 µg kg-1 for
361 the benzimidazole carbamate and amino-benzimidazole SPR-biosensor assays, respectively
362 (Table 4). Samples one to six were determined to be compliant for benzimidazole residues
363 by both the biosensor assay and UHPLC-MS/MS. Two of these samples (five and six)
364 screened above CCβ by the benzimidazole carbamate SPR-biosensor assay, which indicate
365 that they should be sent for confirmatory analysis. A total of four samples (7 to 10) were
366 confirmed to be non-compliant by UHPLC-MS/MS. Three samples (7, 9 and 10) contained
367 residues above their respective MRLs. The remaining sample, number 8, was categorised
368 as non-compliant because it contained MBZ residues, which are not allowed in bovine
369 animals. The benefits of analysing samples using the amino-benzimidazole biosensor
18
370 assay can be seen from the results for samples 8 and 10, which gave a screening response
371 >CCβ. UHPLC-MS/MS confirmed these samples to contain MBZ-NH2 and ABZ-NH2-
372 SO2 residues at 244 and 228 µg kg-1 respectively.
373 One notable aspect of this work was that no amino-benzimidazole response was detected in
374 samples confirmed positive for FBZ residues, particularly samples 7 and 9, which were
375 determined by UHPLC-MS/MS to contain FBZ marker residues at concentrations above
376 1000 µg kg-1.
377
378
379 4. Conclusions
380 The SPR-biosensor assays presented in this work are suitable for use as rapid screening
381 methods for the detection of 11 benzimidazole carbamate residues and four amino-
382 benzimidazole residues in ovine liver tissue. Both assays were validated according to
383 2002/657/EC. The benzimidazole carbamate assay can screen for 11 residues at 50 µg kg-1,
384 equivalent to 25% of the concentration of the lowest MRL for benzimidazole carbamates in
385 liver tissue. The amino-benzimidazole assay can screen for four benzimidazole residues at
386 75 µg kg-1, which is 38% of the lowest MRL for amino-benzimidazoles in liver tissue. No
387 false compliant results occurred during the study and the rate of false non-compliant
388 samples was equal to 5% in both assays. Both screening assays can identify compliant
389 liver tissue samples and thereby reduce the number of samples required to be tested by
390 UHPLC/MS-MS. Only suspect non-compliant samples would then require confirmatory
391 analysis by UHPLC-MS/MS. Using the methodology presented in this paper it is possible
19
392 to extract and analyse 25 samples within a single working day. This is the first reported
393 immunochemical screening assay for amino-benzimidazole residues.
394
395
396 Acknowledgements
397 This research was funded by the Irish Department of Agriculture, Fisheries and Food under
398 the Food Institutional Research Measure as part of the National Development Plan (Project
399 05/R&D/TN/355).
400
401
402 References
403
404 [1] P. Delatour, G. Lorgue, D. Courtot, M. Lampras, Bull. Soc. Sci. Vet. Med. Comp. 77
405 (1975) 197-203.
406 [2] M. Danaher, A.M. Sherry, J. O'Mahony, National Food Residue Database Report 2009.
407 Teagasc, Dublin, 2009.
408 [3] A.M. Marti, A.E. Mooser, H. Koch, J. Chromatogr. A 498 (1990) 145-157.
409 [4] R.T. Wilson, J.M. Groneck, A.C. Henry, L.D. Rowe, J. AOAC Int. 74 (1991) 56-57.
410 [5] G. Domany, L. Koviacs, in: L.A. van Ginkel, A. Ruiter (Eds.), Proceedings of the
411 Euroresidue IV Conference on Residues of Veterinary Drugs in Food, Veldhoven, The
412 Netherlands, May 8-10, National Institute of Public Health and the Environment (RIVM),
413 2000, pp. 361-370.
414 [6] G. Dowling, H. Cantwell, M. O’Keeffe, M.R. Smyth, Anal. Chim. Acta 529 (2005)
415 285-292.
416 [7] B. Kinsella, S.J. Lehotay, K. Mastovska, A.R. Lightfield, A. Furey, M. Danaher, Anal.
417 Chim. Acta 637 (2009) 196-207.
418 [8] P. Delatour, R. Parish, in: A.G. Rico (Ed.), Drug Residues in Animals, Academic Press
419 Inc., Orlando, FL, 1989, pp. 175–204.
420 [9] P. Delatour, F. Garnier, E. Benoit, C. Longin. J. Vet. Pharmacol. Ther. 7 (1984) 139-
421 145.
422 [10] Q.A. McKellar, E.W. Scott, J. Vet. Pharmacol. Ther. 13 (1990) 223-247.
423 [11] D.L. Brandon, R.G. Binder, A.H. Bates, W.C. Montague Jr., J. Agric. Food Chem. 42
424 (1994) 1588-1594.
20
425 [12] A-C, Huet, T. Fodey, S.A. Haughey, S. Weigel, C. Elliott, P. Delahaut., TrAC 29
426 (2010) 1281-1294.
427 [13] L. Johnsson, G.A. Baxter, S.R.H. Crooks, D.L. Brandon C.T. Elliott, Food Agric.
428 Immunol. 14 (2002) 209-21 6.
429 [14] J. Samsonova, G.A. Baxter, S.R.H. Crooks, A.E. Small, C.T. Elliott, Biosens.
430 Bioelectron. 17 (2002) 523-520.
431 [15] S.R.H. Crooks, B. McCarney, I.M. Traynor, C.S. Thompson, S. Floyd, C.T. Elliott,
432 Anal. Chim. Acta, 483 (2003) 181-186.
433 [16] S.R.H. Crooks, G.A. Baxter, M.C. O’Connor, C.T. Elliott, Analyst 123 (1998) 2755.
434 [17] C. Situ, M.H. Mooney, C.T. Elliott, J. Buijs. TrAC 29 (2010) 1305-1315.
435 [18] J. Keegan, M. Whelan, M. Danaher, S. Crooks, R. Sayers, A. Anastasio, C. Elliott, D.
436 Brandon, A. Furey, R. O’Kennedy, Anal. Chim. Acta 654 (2009) 111-119.
437 [19] European Commission Decision 2002/657/EC, Off. J. Eur. Comm. L221 (2002) 1-32.
438 [20] B. Kinsella, M. Whelan, H. Cantwell, M. McCormack, A. Furey, S.J. Lehotay, M.
439 Danaher, Talanta 83 (2010) 14-24.
440
441
442
443
444
445
21
446 Table 1 Maximum residue limits (MRLs) for benzimidazole residues in liver.
447
448 Table 2 Cross-reactivity profile of polyclonal amino-benzimidazole antibody (PAS 9869)
449 polyclonal carboxy-albendazole antibody (S48) in HBS-EP buffer and ovine liver extract.
450
451 Table 3 Determination of detection capability (CCβ) and repeatability of biosensor assays:
452 Results from the analysis of fortified ovine liver (n = 20) and the percentage recovery on
453 different days (n = 5).
454
455 Table 4 Comparison between biosensor and UHPLC-MS/MS analysis of liver samples
456 containing incurred mebendazole, fenbendazole and albendazole residues.
457
458
459 Fig. 1. Comparison of the sensitivity of different extraction methods for ABZ-SO analysis
460 in ovine liver against equivalent curves in HBS-EP buffer.
461
462 Fig. 2. Calibration curves for 11 benzimidazole carbamates in ovine liver matrix.
463
464 Fig. 3 Calibration curves for amino-benzimidazole metabolites in ovine liver matrix.
465
466 Fig. 4. SPR Biosensor assay calibration curves in fortified ovine liver on different days (n
467 = 5) for (A) albendazole sulphone (ABZ-SO2) and (B) albendazole-amino-sulphone (ABZ-
468 NH2-SO2).
Drug Marker residue (possible metabolites)
MRL
(µgkg-
1 )
Animal
species
Albendazole,
Albendazole
sulphoxide
Netobimin
Fenbendazole
Febantel
Fenbendazole-
sulphoxide
Sum of albendazole sulphoxide,
albendazole sulphone, and albendazole
2-amino sulphone, expressed as
albendazole
Sum of extractable residues which
maybe oxidised to fenbendazole
sulphone
1000 All
ruminants
500 All
ruminants
Thiabendazole Sum of thiabendazole and 5- 400 Caprine
hydroxythiabendazole
Flubendazole Sum of flubendazole and amino 400 Avian and
flubendazole porcine
Oxibendazole Oxibendazole 200 Porcine
Triclabendazole Sum of extractable residues that may be
oxidised to keto-triclabendazole
Mebendazole Sum of mebendazole, amino-
mebendazole and hydroxymebendazole,
expressed asmebendazole equivalents
250 All
ruminants
400 Ovine,
Caprine and
Equidae
Table 2
Buffer
Amino-benzimidazole assay
Liver
Analyte aIC50 (ng mL-1) bCR50 (%) cIC50 (µg kg-1) dCR50 (%)
ABZ-NH2-SO2 5.7 100 44 100
FLU-NH2 7.1 80 55 80
MBZ-NH2 5.6 102 39 113
OXI-NH2 4.5 125 35 126
Benzimidazole carbamate assay
aIC50 (ng mL-1) eCR50 (%) cIC50 (µg kg-1) fCR50 (%)
ABZ 4.5 98 90 96
ABZ-SO 4.4 100 86 100
ABZ-SO2 4.8 93 87 99
FBZ 6.6 67 95 91
FBZ-SO 4.0 110 78 110
FBZ-SO2 4.0 110 82 105
MBZ 4.5 98 88 98
MBZ-OH 5.0 88 93 92
FLU 5.5 80 90 96
FLU-OH 6.6 67 89 97
OXI 6.2 71 88 98
a The concentration of analyte required to reduce the response by 50% in HBS-EP buffer.
b Cross-reactivity of antibody towards test amino-benzimidazole at 50% inhibition ((IC50ABZ-NH2-
SO2/IC50 test amino-benzimidazole)x 100) in HBS-EP buffer.
c The concentration of analyte required to reduce the response by 50% in ovine liver.
d Cross-reactivity of antibody towards test amino-benzimidazole at 50% inhibition ((IC50 ABZ-NH2-
SO2/IC50 test amino-benzimidazole)x 100) in ovine liver.
e Cross-reactivity of antibody towards test benzimidazole at 50% inhibition ((IC50 ABZSO/IC50 test
benzimidazole) x100) in HBS-EP buffer.
fCross-reactivity of antibody towards test benzimidazole at 50% inhibition ((IC50 ABZSO/IC50 test
BZT) x 100) in ovine liver.
Table 3
Assay Repeatability Detection Capability
Analyte Mean recovery (%) CV (%) Mean ± S (n = 20) CCβ
± S (n = 5) (n = 5) (µg kg-1)(µg kg-1)
Fortification =100 µg kg-1 Fortification = 50 µg kg-1
ABZ 94 ± 11 11 66 ± 9. <50
ABZ-SO 105 ± 15 15 76 ± 9 <50
ABZ-SO2 122 ± 16 13 71± 5 <50
FBZ 132 ± 15 11 79 ± 8 <50
FBZ-SO2 127 ± 15 12 100 ± 15 <50
OFZ 113 ± 18 17 70 ± 7 <50
FLU 95 ± 13 13 55± 6 <50
FLU-OH 90 ± 9 10 59 ± 8 <50
MBZ 80 ± 11 13 51 ± 9 <50
MBZ-OH 77 ± 9 11 48 ± 11 50
OXI 106 ± 18 17 67 ± 9 <50
Fortification =125 µg kg-1 Fortification = 75 µg kg-1
ABZ-NH2-SO2 109 ± 8 8 121 ± 26 <75
FLU-NH2 110 ± 18 16 87 ± 18 75
MBZ-NH2 116 ± 11 10 93 ± 14 <75
OXI-NH2 103 ± 9 9 105 ± 19 <75
Table 4
Biosensor assays UPLC-MS/MS assaySample Species
Benzimidazole
carbamates (µg kg-1)
Amino-benzimidazoles
(µg kg-1)
aI nterpretation bConcentration
(µg kg-1)
Analyte group cStatus
1 Bovine 14 ND Negative ND ND C
2 Ovine 34 ND Positive 13 FBZ C
3 Ovine 19 ND Negative 7 FBZ C
4 Ovine 12 ND Negative 5 FBZ C
5 Ovine 60 ND Positive 92 FBZ C
6 Ovine 70 ND Positive 75 FBZ C
7 Ovine >1000 ND Positive 2659 FBZ NC
8 Bovine 98 198 Positive 327 MBZ NC
9 Bovine >1000 ND Positive 13096 FBZ NC
10 Bovine >1000 211 Positive 1222 ABZ NC
aNegative samples = < CCβ and positive samples = > CCβ: where benzimidazole carbamate CCβ =50 µg kg-1 and amino-benzimidazole CCβ = 75 µg kg-1
bUPLC-MS/MS concentrations are expressed as the sum of the FBZ, FBZ-SO and FBZ-SO2 residues expressed as FBZ-SO2 , MBZ, MBZ-NH2 and MBZ-OH residues
expressed as MBZ and ABZ, ABZ, ABZ-SO, ABZ-SO2 and ABZ-NH2-SO2 residues expressed as ABZ.
cC = compliant (< MRL) and NC = non-compliant (> MRL).
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